Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

How SARS-CoV-2 affects the male reproductive system

Researchers review the potentially harmful consequences on the male reproductive system in COVID-19 patients.

15 Dec 2021

Evaluation of SARS-CoV-2 Omicron's immune evasion potential

Researchers use VSV vector and Omicron spike protein containing all 32 mutations to create the pseudotyped SARS-CoV-2 Omicron variant (PV-Omicron).

15 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Machine learning method for determining impact of mutations in the SARS-CoV-2 RBD on binding and antibody escape

Deep mutational learning (DML) is a technique developed by researchers from multiple institutions that combines experimental yeast display screening of RBD mutagenesis libraries with deep sequencing and machine learning.

14 Dec 2021

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

A review assessed the impact of "hot" vs. "cold" immune/tumor environments (and associated therapies) on susceptibility and disease course in subjects with these two types of tumors and infected with SARS-CoV-2 to decipher the mechanisms that drive these adverse outcomes in COVID-19 infected cancer patients.

13 Dec 2021